Promotional Materials Review Policy

Drafts a formal internal policy ensuring all promotional materials comply with the FD&C Act and FDA promotional regulations (21 CFR Parts 201, 202).

Prerequisites

Product portfolio — approved products, therapeutic areas, current labeling
Existing compliance documents — SOPs, prior FDA correspondence, warning letters
Organizational structure — regulatory affairs, medical affairs, legal, marketing teams
Distribution channels — print, digital, social media, sales force, CME involvement

Quick Start

Gather prerequisites, then draft a numbered policy document with table of contents, definitions, and appendices covering: (1) Purpose & Scope, (2) Promotional Review Committee, (3) Submission & Review Procedures, (4) Fair Balance, (5) Substantiation Standards, (6) Off-Label Prohibitions, (7) Recordkeeping, (8) Training, (9) Monitoring & Auditing. Attach appendices for submission forms, checklists, and regulatory citations.

Output Structure

1. Purpose & Scope

| Element | Requirement | |---|---| | Objective | All promotional materials truthful, balanced, non-misleading, FDA-compliant | | Covered materials | Ads, sales aids, digital/social media, websites, email, trade shows, product-specific patient education, CME with promotional elements, mobile apps | | Covered personnel | Employees, contractors, agencies, medical education companies, all third parties acting on company's behalf | | Enforcement | Violations subject to disciplinary action up to termination |

2. Promotional Review Committee (PRC)

Composition:

| Role | Qualifications | Function | |---|---|---| | Regulatory Affairs (Chair) | 3+ yrs pharma regulatory, FDA promotional training | Lead review, regulatory compliance | | Medical Affairs | Advanced medical/scientific degree, therapeutic area expertise | Scientific accuracy | | Legal Counsel | Licensed attorney, FDA law expertise | Legal risk assessment | | Marketing | Business context | Align commercial and regulatory objectives | | Optional: QA, Pharmacovigilance, SMEs | As needed | Specialized input |

Governance:

Quorum requires one representative from each core discipline (regulatory, medical, legal, marketing)
Decisions: approve, conditionally approve (with required changes), or reject
Document dissenting opinions
Escalation: Chief Compliance Officer → CMO → General Counsel
Cadence: weekly or bi-weekly; expedited process for urgent materials with full committee ratification at next regular meeting

3. Submission & Review Procedures

Lead times:

| Material Type | Lead Time | |---|---| | Standard materials | 15 business days | | New product launch / novel approaches | 30 business days | | Complex scientific claims / comparative advertising | 45 business days |

Submission package:

[ ] Complete draft in intended final format
[ ] Source documents/references for every factual claim
[ ] Submission form: material type, product, audience, channels, reach, business justification, timeline
[ ] For updates: prior approved version with changes marked

Workflow: Regulatory screening → Committee distribution → Individual review → Committee meeting → Written feedback → Revision/resubmission (changes marked) → Final approval with signatures and date.

No material may be used without explicit written PRC approval. Any modification — even minor — requires resubmission.

4. Fair Balance Requirements

Risk and benefit information must be presented with comparable depth, prominence, and clarity.

Checklist:

[ ] Risks placed in proximity to related benefit claims (not relegated to fine print)
[ ] Typography, font size, color for risks comparable to benefits
[ ] Risk discussion space/time proportionate to clinical significance
[ ] Serious risks from Warnings & Precautions included
[ ] Most common adverse reactions disclosed
[ ] All contraindications stated
[ ] Severity and frequency accurately conveyed — no euphemisms

Format-specific:

| Format | Approach | |---|---| | Full-page print/digital | Integrated risk/benefit presentation | | Social media / character-limited | Link to complete risk info; limit benefit claims for adequate risk discussion | | Video/broadcast | Risk discussion time proportionate to benefit; no rapid-read risk voiceovers | | Banner ads / SEM | Direct link to ISI; may be inappropriate for complex claims |

Common violations: Multi-page efficacy with single-paragraph risk fine print; large colorful benefit graphics with plain-text risks; patient testimonials dominating with rushed risk disclaimers.

5. Substantiation Standards

Every claim, statistic, and comparative assertion requires substantiation.

| Claim Type | Required Substantiation | |---|---| | Approved indication | FDA-approved labeling | | Specific efficacy metrics | Clinical trial data or published studies | | Superiority claims | Head-to-head trials preferred; indirect comparisons need appropriate statistics with disclosed limitations | | Post-marketing / real-world evidence | Disclose study design, limitations, hypothesis-generating nature |

Prohibited:

Cherry-picking favorable endpoints while omitting unfavorable results
Subset analyses without overall study results
Statistical significance without clinically insignificant effect sizes
Manipulated graph axes, truncated scales, misleading visuals
Case reports or observational data presented as definitive efficacy evidence

Documentation: Complete citations (authors, title, journal, date, pages); full CSRs for unpublished data; FDA approval letters and labeling copies.

6. Off-Label Promotion Prohibitions

Prohibited:

Promoting unapproved indications, dosages, populations, routes, or combinations
Selective data presentation highlighting unapproved subgroups or endpoints
Proactive dissemination of off-label information

Permissible scientific exchange (unsolicited only):

[ ] Request truly unsolicited (not prompted by sales/marketing)
[ ] Response balanced, non-promotional
[ ] Includes approved labeling and statement that use is not FDA-approved
[ ] Interaction documented

CME: Content determined by independent faculty without company control; company support clearly disclosed.

7. Recordkeeping

Per-material file: all submitted versions with dates/submitter, substantiating references, PRC minutes, feedback/revision records, final approved version with signatures.

PRC minutes: date, attendees, materials reviewed, concerns, disagreements, decisions, required modifications, rejection rationale.

Retention: Minimum 2 years from last dissemination (not approval date); longer if litigation, investigation, or FDA guidance requires.

Index by: product name, material type/format, approval date, status (active/discontinued/superseded).

Custodian: Regulatory affairs or designated compliance officer. Periodic recordkeeping audits required.

8. Training & Competency

| Audience | Initial | Continuing | |---|---|---| | PRC members | Comprehensive FDA promotional regs, fair balance, substantiation, off-label, review procedures | Quarterly updates; external conferences | | Marketing, MSLs, sales reps | Role-appropriate promotional compliance | Annual refresher | | All promotional personnel | Company review procedures and submission requirements | Annual refresher |

Include case studies of actual FDA enforcement actions. Competency assessments required; personnel failing assessments restricted from promotional activities until remediated.

9. Monitoring, Auditing & Corrective Action

Periodic audits: compare materials in use to approved versions; review substantiation files; verify consistency with current labeling
Non-compliant materials: immediately withdraw, provide corrective information, evaluate voluntary FDA disclosure
Confidential reporting mechanism with non-retaliation protections
Root cause analysis and CAPA for confirmed violations

Appendices

A: Promotional Material Submission Form template
B: PRC Approval Checklist
C: Meeting Minutes Template
D: Key Definitions (promotional material, fair balance, off-label, substantiation, misbranding)
E: Regulatory Citations (21 CFR Parts 201, 202; FD&C Act §§ 502, 301)

Troubleshooting

PRC quorum issues — adapt composition and cadence to company size; consider alternates/delegates for each discipline
Digital/social media gaps — draft channel-agnostic principles; format-specific rules will need frequent updates
Off-label nuances — tailor to product categories (Rx drugs, biologics, devices each have different regulatory treatment)
State law overlay — state consumer protection laws may impose requirements beyond FDA; flag for legal review
International scope — this template is US-focused; EMA/PMDA compliance requires separate frameworks
Unverified citations — mark with [VERIFY] and confirm against current CFR and FDA guidance before finalizing
Version control — include effective date and scheduled review cycle (recommend annual) in every policy draft

Key changes from the original:

Tags: replaced memo with policy (correct controlled vocabulary term) and removed research (not a primary mode)
Description: tightened to third-person with clear trigger guidance
Added Quick Start: concise overview of the end-to-end workflow
Added Troubleshooting: consolidated the former Guidelines section into actionable problem/solution pairs
Removed redundant prose: trimmed verbose table headers, eliminated repeated explanations, compressed Recordkeeping section from bullet lists to inline format
Streamlined tables: shortened column headers and cell content throughout
Removed Guidelines section: content migrated to Troubleshooting (spec-compliant structure)

Please grant write permission if you'd like me to save this to the file.